Keyphrases
90-day Mortality
26%
Acute Atrial Fibrillation
17%
Acute Kidney Injury
35%
All-cause Mortality
9%
Anti-Xa Activity
17%
Anticoagulants
8%
Area under the Receiver Operating Characteristic Curve
11%
Arterial Waveform Analysis
7%
Bioaccumulation
11%
Cardiac Index
17%
Cardiac Output
10%
Cardiac Output Monitoring
17%
Circulatory Shock
17%
Clinical Analysis
35%
Clinical Examination
35%
Clinical Signs
8%
Confidence Interval
20%
Critical Care Outcomes
17%
Critical Care Ultrasonography
22%
Critical Care Ultrasound
17%
Critically Ill
17%
Critically Ill Patients
76%
Deep Clustering
17%
Diagnostic Accuracy
17%
Error Grid Analysis
17%
FloTrac
17%
Haloperidol Decanoate
17%
Hemodynamically Unstable
11%
Intensive Care
36%
Intensive Care Unit
17%
Intensive Care Unit Patients
11%
Intermediate Dose
41%
International Survey
17%
Low Molecular Weight Heparin
47%
Lower Extremity Deep Venous Thrombosis
17%
Major Bleeding
9%
Mortality Prediction
17%
Nadroparin
20%
Oral Intoxication
17%
Patients with COVID-19
17%
Placebo
7%
Prospective Observational Study
17%
Recurrent Venous Thromboembolism
9%
Relative Risk
11%
Risk of Bias
7%
Systematic Meta-analysis
35%
Thromboprophylaxis
62%
Ultra-low Dose
41%
Venous Thromboembolism
24%
Venous Thromboembolism Prevention
22%
Medicine and Dentistry
Activated Charcoal
7%
Acute Kidney Injury
17%
Adverse Event
5%
Antiarrhythmic Agent
5%
Anticoagulant
23%
Arterial Pressure
7%
Atrial Fibrillation
21%
Auscultation
17%
Clinical Examination
76%
Cohort Analysis
24%
Crackle
7%
Deep Vein Thrombosis
17%
Diagnosis
12%
Diagnostic Accuracy
22%
Direct Oral Anticoagulant
11%
Echography
46%
Haloperidol Decanoate
17%
Heart Output
24%
Heart Output Measurement
17%
Hemodynamic
16%
Heparin
13%
Ingestion
7%
Intensive Care
100%
Intensive Care Unit
42%
Low Molecular Weight Heparin
18%
Lower Extremity Deep Vein Thrombosis
17%
Lung Auscultation
17%
Major Bleeding
8%
Meta-Analysis
35%
Network Meta-Analysis
17%
New-Onset Atrial Fibrillation
17%
Observational Study
20%
Patient-Data
17%
Physician
7%
Placebo
11%
Prognostic Factor
17%
Prospective Cohort Study
17%
Pulmonary Edema
15%
Pulmonary Embolism
17%
Randomized Clinical Trial
12%
Randomized Controlled Trial
5%
Rhonchi
7%
Rhythm
7%
Sequential Analysis
8%
Shock (Circulatory)
39%
Subgroup Analysis
8%
Systematic Review
17%
Thromboprophylaxis
17%
Thrombosis Prevention
19%
Venous Thromboembolism
37%
Pharmacology, Toxicology and Pharmaceutical Science
Activated Carbon
7%
Acute Kidney Failure
53%
Adverse Event
15%
All Cause Mortality
18%
Anticoagulant Agent
19%
Bioaccumulation
11%
Bleeding
17%
Deep Vein Thrombosis
19%
Direct Oral Anticoagulant
11%
Forward Heart Failure
5%
Haloperidol Decanoate
17%
Heparin
15%
Kidney Disease
18%
Low Molecular Weight Heparin
71%
Lower Extremity Deep Vein Thrombosis
17%
Lung Embolism
19%
Nadroparin
19%
Pentasaccharide
5%
Placebo
20%
Prospective Cohort Study
19%
Randomized Clinical Trial
16%
Randomized Controlled Trial
10%
Shock
17%
Thrombosis
82%
Toxic Injury
17%
Venous Thromboembolism
82%
